International Conference on Advanced Functional Materials and Technologies (ICAFMT)
Meeting Announcement
Driven by a new wave of technological revolution, materials science is transforming. To capture this momentum, the International Conference on Advanced Functional Materials and Technologies (ICAFMT) will be convened in Dongguan, China, from October 23-25, 2026.
ICAFMT26 is dedicated to bridge the gap between advanced materials and intelligent science. By providing a platform for in-depth discussion on new trends, it aims to promote international collaboration and drive global innovation.
The Hospital Pharmacy Research Summit & Face-to-Face with SCI Journal Editors/Publisher, organized by the China Medical Education Association (CMEA) , was held on May 30, 2026 at Hangzhou Zhongwei Xiangyi Hotel. Chaired by Prof. Haibin Dai, the event featured discussions on research mindset, academic writing, submission strategies, and research integrity, beginning with his opening address.
CHICAGO, MAY 31, 2026 ― Updated results from the Phase 3 BREAKWATER trial, led by researchers at The University of Texas MD Anderson Cancer Center, demonstrated a 56% reduction in the risk of disease progression or death for patients with BRAF V600E mutant metastatic colorectal cancer treated with a targeted therapy combination.
Experts from NYU Langone Health’s Perlmutter Cancer Center, a National Cancer Institute–designated Comprehensive Cancer Center, present their latest clinical findings and research at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 29 to June 2 in Chicago.
Insilico Medicine will present its latest advances in generative AI-driven drug discovery, quantum-enabled research, and clinical development at the BIO 2026 International Convention in San Diego. The company will participate in three featured speaking sessions covering China’s impact on biotech business development, quantum computing in drug discovery, and strategies for building smarter pipelines for challenging targets. Insilico will also showcase its Pharma.AI platform, LifeStar 2 laboratory, and MMAI Gym for Science while meeting with biopharma partners, investors, and researchers at Booth #4021.
Insilico highlighted progress across its growing pipeline, including Rentosertib, the world’s first AI-discovered anti-fibrotic candidate with a novel mechanism of action, which has completed a Phase 2a proof-of-concept trial. The company also shared updates on ISM5411 for inflammatory bowel disease and multiple oncology programs that have reached first-in-patient dosing. Since its founding in 2014, Insilico has published more than 200 peer-reviewed papers and was recently recognized among the top global corporate research institutions in Nature Index rankings.